May 23 (Reuters) - Allergan Inc Chief Executive
Brent Saunders said on Monday the company expects to close the
$40.5 billion sale of its generic medicines portfolio to Teva
Pharmaceutical Industries Ltd in a matter of weeks,
opening the door for new acquisitions.
Read more
No comments:
Post a Comment